ARTICLE | Emerging Company Profile

Wugen: deploying memory NK cells against cancer

And turning allogeneic CAR T cells against T cell malignancies

May 17, 2021 6:08 PM UTC

Wugen is adding a new subset of NK cells to the cell therapy toolkit with its memory NK cell approach, which may lead to high antitumor efficacy without requiring a CAR or other modifications. 

The company was formed in 2018 to develop off-the-shelf CAR T cell therapies, but broadened its scope to include memory NK cells after in-licensing the technology from Washington University in St. Louis last year...

BCIQ Company Profiles

Wugen Inc.